Source: StreetInsider

Press Release: RA Capital : RA Capital Management Opposes BioCryst Pharmaceuticals' Proposed Merger with Idera Pharmaceuticals

BOSTON, April 2, 2018 /PRNewswire/ -- RA Capital Management, LLC ("RA Capital") today announced that it delivered a letter to the Board of Directors of BioCryst Pharmaceuticals, Inc. ("BioCryst") conveying its opposition to BioCryst's proposed merger with Idera Pharmaceuticals, Inc. and its intention to vote against the proposed merger at the upcoming special meeting of stockholders scheduled to be held on May 9, 2018. The full text of the letter is below and will also be included as an exhibit to RA Capital's Schedule 13D to be filed with the SEC.

Read full article »

Top Competitors or Alternatives

Missing a competitor? Contribute!

Est. Annual Revenue
Est. Employees
Peter Kolchinsky's photo - Managing Partner of RA Capital

Managing Partner

Peter Kolchinsky

CEO Approval Rating

68/100

RA Capital Management is a venture capital firm that invests in healthcare and life-sciences companies. Read more